Lowering the Triglyceride/High-Density Lipoprotein Cholesterol Ratio Is Associated With the Beneficial Impact of Pioglitazone on Progression of Coronary Atherosclerosis in Diabetic Patients: Insights From the PERISCOPE (Pioglitazone Effect on Regression o

详细信息    查看全文

• 作者：Stephen J. Nicholls MBBS ; PhD ; ^† ; ; ^‡ ; ; ^{nichols1@ccf.org} ; E. Murat Tuzcu MD ; Kathy Wolski MPH ; Ozgur Bayturan MD ; Andrea Lavoie MD ; Kiyoko Uno MD ; Stuart Kupfer MD^§ ; ; Alfonso Perez MD^§ ; ; Richard Nesto MD ; Steven E. Nissen MD
• 关键词：atherosclerosis ; diabetes ; intravascular ultrasonography
• 刊名：Journal of the American College of Cardiology
• 出版年：2011
• 出版时间：11 January 2011
• 年：2011
• 卷：57
• 期：2
• 页码：153-159
• 全文大小：220 K

文摘

Objectives

The purpose of this study was to determine the factors associated with the favorable effect of pioglitazone on atheroma progression.

Background

Diabetes mellitus is associated with accelerated coronary atheroma progression. Pioglitazone slowed progression compared with glimepiride in this population.

Methods

In all, 360 diabetic patients with coronary artery disease were treated with pioglitazone or glimepiride for 18 months in the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. Coronary atheroma progression was evaluated by serial intravascular ultrasound. The relationship between changes in biochemical parameters, percent atheroma volume, and total atheroma volume was investigated.

Results

Pioglitazone-treated patients demonstrated greater increases in high-density lipoprotein cholesterol (HDL-C) and reductions in glycated hemoglobin, triglycerides, and C-reactive protein. Significant correlations were observed between changes in percent atheroma volume and triglycerides (r = 0.15, p = 0.04), triglyceride/HDL-C ratio (r = 0.16, p = 0.03), and glycated hemoglobin (r = 0.16, p = 0.03) with pioglitazone, and changes in low-density lipoprotein cholesterol (r = −0.15, p = 0.05), apolipoprotein B (r = −0.16, p = 0.04), and apolipoprotein A-I (r = −0.20, p = 0.01) with glimepiride. Substantial atheroma regression, compared to progression, was associated with greater relative increases in HDL-C (14.2 % vs. 7.8 % , p = 0.04), relative decreases in triglycerides (−13.3 % vs. −1.9 % , p = 0.045), triglyceride/HDL-C ratio (−22.5 vs. −9.9 % , p = 0.05), and decrease in glycated hemoglobin (−0.6 % vs. −0.3 % , p = 0.01). Multivariable analysis revealed that pioglitazone-induced effects on triglyceride/HDL-C were associated with changes in percent atheroma volume (p = 0.03) and total atheroma volume (p = 0.02).

Conclusions

Favorable effects of pioglitazone on the triglyceride/HDL-C ratio correlated with delayed atheroma progression in diabetic patients. This finding highlights the potential importance of targeting atherogenic dyslipidemia in diabetic patients with coronary artery disease.